Strategies in the management of acute myocardial infarction

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Clinical trials continue to evaluate the pharmacologic management of myocardial infarction for benefits in mortality, degree of infarct artery patency, and frequency of reocclusion. The discovery of thrombus formation in the development of the myocardial infarction renewed interest in thrombolytic therapy. In appropriate candidates, timely administration of thrombolytic after myocardial infarction restores coronary artery patency, reduces myocardial ischemic damage, and improves left ventricular function. Adjunct therapy for thrombolysis typically includes aspirin, heparin, β-blockers, nitroglycerin, and angiotensin-converting enzyme inhibitors, if not contraindicated. To reduce cardiac risk, postthrombolysis management generally includes aspirin, β-blockers, and angiotensin-converting enzyme inhibitors together with efforts to reduce known cardiovascular risk factors.

Original languageEnglish (US)
Pages (from-to)127S-136S
Issue number5 II
StatePublished - Sep 1 1996

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Strategies in the management of acute myocardial infarction'. Together they form a unique fingerprint.

Cite this